Esperion Therapeutics, Inc. Aktie News

ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced the pricing of an underwritten public offering...

ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced that it has commenced an underwritten public o...

ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. and its affiliate Dr. Reddy's Laboratories Ltd. (together, Dr. Reddy's Laboratories). This agreement resolves the patent litigation brought by Esperion against Dr. Reddy's Laboratories in response to Dr. Reddy's Laborator...

Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL

Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Cantor Global Healthcare Conference 2025 September 3, 2025 9:45 AM EDT Company Participants Benjamin Halladay - Chief Financial Officer Sheldon Koenig - President, CEO & Director Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Presentation Kristen Kluska Analyst Okay. Good morning, everybody.

– Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence –

ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.

Esperion (ESPR) Q2 Revenue Jumps 12%